SEC FORM 3

SEC FORM 3SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Denoyer Bernard

(Last)

(First)

(Middle)

C/O OKYO PHARMA LTD,

14-15 CONDUIT STREET

(Street)

LONDON

W1S 2XJ

(City)

(State)

(Zip)

UNITED KINGDOM

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
OKYO Pharma Ltd [ OKYO ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Options	03/14/2024	03/14/2033	common stock	770	$2.13	D
Options	03/14/2025	03/14/2033	common stock	769	$2.13	D
Options	03/14/2026	03/14/2033	common stock	769	$2.13	D
Options	03/14/2027	03/14/2033	common stock	769	$2.13	D
Options	03/13/2025	03/13/2034	common stock	3,333	$1.46	D
Options	03/13/2026	03/13/2034	common stock	3,334	$1.46	D
Options	03/13/2027	03/13/2034	common stock	3,333	$1.46	D
Options	01/29/2026	01/29/2035	common stock	1,204	$1.6	D
Options	01/29/2027	01/29/2035	common stock	1,204	$1.6	D
Options	01/29/2028	01/29/2035	common stock	1,205	$1.6	D
Options	03/25/2026	03/25/2035	common stock	3,750	$1.5	D
Options	03/25/2027	03/25/2035	common stock	3,750	$1.5	D
Options	03/25/2028	03/25/2035	common stock	3,750	$1.5	D
Options	03/25/2029	03/25/2035	common stock	3,750	$1.5	D

Explanation of Responses:

	/s/ Bernard Denoyer	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)